981P - Epidemiology projection trends for ovarian cancer (OC) patients by platinum response status in Europe and U.S.
|Date||29 September 2012|
|Event||ESMO Congress 2012|
|Session||Poster presentation I|
|Topics|| Ovarian Cancer
Cancer Aetiology, Epidemiology, Prevention
J. Mehta1, R. Olivares2, O. Moulard2, P. Trask3, A. Hamed1
Ovarian cancer is the eighth most commonly diagnosed cancer among women worldwide with an estimated 225,500 new cases and 140,000 deaths per year. There is a lack of published data on the distribution of patients across lines of therapy based on their platinum response status i.e. platinum resistant/refractory or platinum-sensitive.
|Year||Line of therapy*||Number of patients|
|2L Platinum Sensitive||1448||2711||1604||947||1937||8647||4546|
|2L Platinum Refractory||1196||2238||1324||782||1599||7139||2557|
|2L Platinum Sensitive||1631||2874||1767||1098||2069||9439||5354|
|2L Platinum Refractory||1346||2373||1458||906||1708||7791||3011|
*patient may receive multiple lines of therapy in given year; **stage II, III, IV combined; ^ for US, includes 3L + 4L; NA = not available Source: CancerMPact® Kantar Health (www.cancermpact.com) Accessed Mar 2011 for EU, Jan 2012 for USMethods
Epidemiological data was obtained for US and EU using CancerMPact® database. This database includes line of therapy estimations using the US National Oncology Data Alliance numbers combined with a survey of a representative sample of physicians in the U.S. and Europe. Using historical data, we analyzed projection estimates up to 2020 across US and EU5 countries by line of therapy and platinum response status.Results
Projection estimates from 2010 to 2020 by line of therapy varied by country. Among EU countries, the highest number of treated patients was in Germany, followed by United Kingdom (UK) and Italy. By 2020, the percentages of patients that are platinum sensitive and platinum refractory are expected to increase by about 17% in the US and 9% in the EU. Regional variation was observed across Europe with percentage increase in France being 12%, Germany 6%, Italy 10%, Spain 16% and UK 7%. The table below refers to the number of ovarian cancer patients by line of therapy.Conclusions
Despite ongoing therapeutic efforts, only 44%of patients in US and 65% in EU who receive 1L go on to 2L. This argues for continued efforts to be made for the development of more efficacious treatments for ovarian cancer. Real world data and disease based registries can help in validating emerging trends in therapy through providing up to date global projection estimates across line of therapy.Disclosure
J. Mehta: Employee of Sanofi R. Olivares: Employee of Sanofi O. Moulard: Employee of Sanofi P. Trask: Employee of Sanofi and owns stock A. Hamed: Employee of Sanofi.